HIV Infections, Leukoplakia, Hairy
Conditions
Keywords
AIDS-Related Opportunistic Infections, Leukoplakia, Oral, Herpesvirus 4, Human, Acyclovir, AIDS-Related Complex
Brief summary
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.
Interventions
DRUGAcyclovir
Sponsors
Glaxo Wellcome
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Concurrent Medication: Allowed: * Topical antifungal therapy. Patient must have: * Newly diagnosed clinical and histological hairy leukoplakia. * Positive HIV antibody by licensed ELISA or Western blot.
Exclusion criteria
Co-existing Condition: Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Concurrent Medication: Excluded within 2 weeks of study entry: * Systemic antifungal treatment. * Excluded within 6 weeks of study entry: * Immunomodulators. * Systemic antiviral treatment. Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Prior Medication: Excluded within 2 weeks of study entry: * Systemic antifungal. * Excluded within 6 weeks of study entry: * Immunomodulators. * Systemic antiviral treatment. * Excluded within 8 weeks of study entry: * Zidovudine (AZT) or other antiretroviral therapy.
Countries
United States
Outcome results
None listed